JP2013527168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527168A5 JP2013527168A5 JP2013508244A JP2013508244A JP2013527168A5 JP 2013527168 A5 JP2013527168 A5 JP 2013527168A5 JP 2013508244 A JP2013508244 A JP 2013508244A JP 2013508244 A JP2013508244 A JP 2013508244A JP 2013527168 A5 JP2013527168 A5 JP 2013527168A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- protein
- composition according
- item
- terminus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 29
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 230000001177 retroviral effect Effects 0.000 claims description 5
- 102000044489 human CD24 Human genes 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 235000018102 proteins Nutrition 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32907810P | 2010-04-28 | 2010-04-28 | |
| US61/329,078 | 2010-04-28 | ||
| PCT/US2011/034282 WO2011139820A1 (en) | 2010-04-28 | 2011-04-28 | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015137457A Division JP6062502B2 (ja) | 2010-04-28 | 2015-07-09 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527168A JP2013527168A (ja) | 2013-06-27 |
| JP2013527168A5 true JP2013527168A5 (enExample) | 2014-06-19 |
| JP5899206B2 JP5899206B2 (ja) | 2016-04-06 |
Family
ID=44903987
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508244A Expired - Fee Related JP5899206B2 (ja) | 2010-04-28 | 2011-04-28 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
| JP2015137457A Expired - Fee Related JP6062502B2 (ja) | 2010-04-28 | 2015-07-09 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
| JP2016242313A Withdrawn JP2017057216A (ja) | 2010-04-28 | 2016-12-14 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
| JP2018094404A Expired - Fee Related JP6526872B2 (ja) | 2010-04-28 | 2018-05-16 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
| JP2019088170A Expired - Fee Related JP6888221B2 (ja) | 2010-04-28 | 2019-05-08 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015137457A Expired - Fee Related JP6062502B2 (ja) | 2010-04-28 | 2015-07-09 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
| JP2016242313A Withdrawn JP2017057216A (ja) | 2010-04-28 | 2016-12-14 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
| JP2018094404A Expired - Fee Related JP6526872B2 (ja) | 2010-04-28 | 2018-05-16 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
| JP2019088170A Expired - Fee Related JP6888221B2 (ja) | 2010-04-28 | 2019-05-08 | 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8808697B2 (enExample) |
| EP (3) | EP2563385B1 (enExample) |
| JP (5) | JP5899206B2 (enExample) |
| KR (1) | KR20130086126A (enExample) |
| CN (2) | CN105381451B (enExample) |
| AU (1) | AU2011248540B2 (enExample) |
| CA (1) | CA2795823C (enExample) |
| DK (1) | DK2563385T3 (enExample) |
| EA (2) | EA036805B8 (enExample) |
| ES (2) | ES2826445T3 (enExample) |
| IL (1) | IL222739A0 (enExample) |
| NO (1) | NO2563385T3 (enExample) |
| NZ (1) | NZ603196A (enExample) |
| PL (2) | PL3260128T3 (enExample) |
| PT (2) | PT2563385T (enExample) |
| SG (1) | SG184907A1 (enExample) |
| WO (1) | WO2011139820A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
| HK1249521A1 (zh) * | 2015-05-07 | 2018-11-02 | 肿瘤免疫股份有限公司 | Cd24用於降低低密度脂蛋白胆固醇水平的用途 |
| WO2017136492A1 (en) * | 2016-02-02 | 2017-08-10 | Oncoimmune, Inc. | Use of cd24 proteins for treating leptin-deficient conditions |
| US10758574B2 (en) | 2016-04-28 | 2020-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy |
| KR101789449B1 (ko) * | 2016-12-08 | 2017-10-23 | 박문수 | 폐유지를 이용한 지방산 메틸에스테르 제조방법 |
| EP3592375A4 (en) | 2017-03-07 | 2021-01-20 | Oncoimmune, Inc. | METHOD OF USING SOLUBLE CD24 FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS |
| CN110650749A (zh) * | 2017-05-15 | 2020-01-03 | 肿瘤免疫股份有限公司 | 使用可溶性cd24进行神经保护和髓鞘再生的方法 |
| WO2018217659A1 (en) * | 2017-05-22 | 2018-11-29 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies |
| SG11202007815TA (en) * | 2018-03-05 | 2020-09-29 | Oncoimmune Inc | Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids) |
| KR20250122537A (ko) * | 2018-05-14 | 2025-08-13 | 온코씨4, 아이앤씨. | 항-cd24 조성물 및 이의 용도 |
| WO2019236474A1 (en) * | 2018-06-04 | 2019-12-12 | Oncoimmune, Inc. | Methods of use of cd24 for the prevention and treatment of leukemia relapse |
| EP4017508A1 (en) * | 2019-08-23 | 2022-06-29 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
| CN112480237B (zh) * | 2019-09-12 | 2023-10-17 | 上海津曼特生物科技有限公司 | 一种融合蛋白及其制备方法和应用 |
| US20250195673A1 (en) * | 2020-11-30 | 2025-06-19 | Fred Hutchinson Cancer Center | Compositions and methods for selective depletion of target molecules |
| CN118076625A (zh) * | 2021-09-28 | 2024-05-24 | 广州昂科免疫生物技术有限公司 | 包含071核心肽的融合蛋白及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5759775A (en) * | 1994-10-27 | 1998-06-02 | Genetech, Inc. | Methods for detecting nucleic acids encoding AL--1 neurotrophic factor |
| CN101254302B (zh) * | 1999-05-07 | 2011-05-11 | 杰南技术公司 | 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病 |
| AU2001259792B2 (en) * | 2000-03-29 | 2005-12-22 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive T cells |
| US20030106084A1 (en) * | 2000-03-29 | 2003-06-05 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
| US20030095966A1 (en) * | 2000-03-29 | 2003-05-22 | Yang Liu | Method of blocking tissue destruction by autoreactive T cells |
| AU2002233340B2 (en) * | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| US20050214290A1 (en) * | 2001-03-29 | 2005-09-29 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
| PL367329A1 (en) * | 2001-07-13 | 2005-02-21 | Merck Patent Gmbh | Methods for reducing immunogenicity of polypeptides |
| EP2292259A3 (en) * | 2002-11-15 | 2011-03-23 | MUSC Foundation For Research Development | Complement receptor 2 targeted complement modulators |
| HRP20090325T1 (en) * | 2003-04-09 | 2009-07-31 | Genentech | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
| AU2007242919B8 (en) * | 2003-04-09 | 2011-11-10 | F. Hoffmann-La Roche Ag | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor |
| AU2004294547A1 (en) * | 2003-11-26 | 2005-06-16 | The Ohio State University Research Foundation | Polymorphic CD24 genotypes that are predictive of multiple sclerosis risk and progression |
| WO2005113599A1 (en) * | 2004-05-21 | 2005-12-01 | Xencor, Inc. | C1q family member proteins with altered immunogenicity |
| US20060160220A1 (en) * | 2004-11-12 | 2006-07-20 | Iogenetics | Retroviral vectors with introns |
-
2011
- 2011-04-28 JP JP2013508244A patent/JP5899206B2/ja not_active Expired - Fee Related
- 2011-04-28 AU AU2011248540A patent/AU2011248540B2/en not_active Ceased
- 2011-04-28 DK DK11778000.7T patent/DK2563385T3/da active
- 2011-04-28 EA EA201790538A patent/EA036805B8/ru unknown
- 2011-04-28 NZ NZ603196A patent/NZ603196A/en not_active IP Right Cessation
- 2011-04-28 KR KR1020127028301A patent/KR20130086126A/ko not_active Withdrawn
- 2011-04-28 EP EP11778000.7A patent/EP2563385B1/en active Active
- 2011-04-28 CA CA2795823A patent/CA2795823C/en active Active
- 2011-04-28 PT PT117780007T patent/PT2563385T/pt unknown
- 2011-04-28 ES ES17183045T patent/ES2826445T3/es active Active
- 2011-04-28 EA EA201290961A patent/EA027735B1/ru unknown
- 2011-04-28 SG SG2012077095A patent/SG184907A1/en unknown
- 2011-04-28 ES ES11778000.7T patent/ES2645262T3/es active Active
- 2011-04-28 WO PCT/US2011/034282 patent/WO2011139820A1/en not_active Ceased
- 2011-04-28 US US13/643,527 patent/US8808697B2/en active Active
- 2011-04-28 PL PL17183045T patent/PL3260128T3/pl unknown
- 2011-04-28 CN CN201510683408.8A patent/CN105381451B/zh not_active Expired - Fee Related
- 2011-04-28 EP EP17183045.8A patent/EP3260128B1/en active Active
- 2011-04-28 PL PL11778000T patent/PL2563385T3/pl unknown
- 2011-04-28 EP EP20188241.2A patent/EP3845238A1/en not_active Withdrawn
- 2011-04-28 NO NO11778000A patent/NO2563385T3/no unknown
- 2011-04-28 PT PT171830458T patent/PT3260128T/pt unknown
- 2011-04-28 CN CN201180021423.6A patent/CN102869369B/zh not_active Expired - Fee Related
-
2012
- 2012-10-28 IL IL222739A patent/IL222739A0/en active IP Right Grant
-
2015
- 2015-07-09 JP JP2015137457A patent/JP6062502B2/ja not_active Expired - Fee Related
-
2016
- 2016-12-14 JP JP2016242313A patent/JP2017057216A/ja not_active Withdrawn
-
2018
- 2018-05-16 JP JP2018094404A patent/JP6526872B2/ja not_active Expired - Fee Related
-
2019
- 2019-05-08 JP JP2019088170A patent/JP6888221B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527168A5 (enExample) | ||
| Yuan et al. | A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV | |
| ES2312205T3 (es) | Nuevo polipeptido y acidos nucleicos que lo codifican. | |
| Ko et al. | An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies | |
| EP0528926B1 (en) | Soluble peptide analogues containing binding sites | |
| Yang et al. | Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues | |
| ES2552954T3 (es) | Anticuerpos anti-C5a y métodos para el uso de los anticuerpos | |
| ES3037854T3 (en) | D-domain containing polypeptides and uses thereof | |
| ES2968439T3 (es) | Anticuerpos FcRn y procedimientos de uso de los mismos | |
| FI3368555T3 (fi) | Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus | |
| RU2015142999A (ru) | Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения | |
| JP2017527272A5 (enExample) | ||
| RU2007125381A (ru) | Варианты il-7 со сниженной иммуногенностью | |
| ES2655941T3 (es) | Proteína de fusión | |
| JPH05505112A (ja) | Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ | |
| WO2010105573A1 (zh) | 抗血管新生融合蛋白 | |
| NO330221B1 (no) | Anvendelse av en antagonist for integrin <alfa>-4-subenheten for fremstilling av et medikament til behandling av fibrose | |
| PT98394B (pt) | Processo para a preparacao de formas multimericas da proteina receptora de rinovirus humano | |
| Geng et al. | Cartilage oligomeric matrix protein specific antibodies are pathogenic | |
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| EA036805B1 (ru) | Белок cd24 для подавления повреждения ткани, опосредованного damp | |
| JP2008531746A5 (enExample) | ||
| JP2019506408A5 (enExample) | ||
| Kowalczyk et al. | Molecular and therapeutic characterization of anti-ectodysplasin A receptor (EDAR) agonist monoclonal antibodies | |
| Cano-Munoz et al. | Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity |